Sugi Predict

Sugi Predict / Compounds / SCHEMBL6438284

SCHEMBL6438284

SCHEMBL6438284

O=C(C=Cc1ccc(C2=C(c3ccccc3)CCCc3ccccc32)cc1)NS(=O)(=O)Cc1ccc(F)cc1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 8/20 0.42
▸ ESR2 Q92731 6/20 0.42
▸ KDM1A O60341 1/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ GPR183 P32249 1/20 0.38
▸ PTGS2 P35354 3/20 0.38
▸ PTGS1 P23219 1/20 0.38
▸ NOS3 P29474 1/20 0.37
▸ NOS1 P29475 1/20 0.37
▸ NOS2 P35228 1/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ HTT P42858 1/20 0.36
▸ POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6438282 1.00 ESR1 (0.42) ESR1ESR2KDM1AHDAC1GPR183
SCHEMBL6437030 0.94 HDAC1 (0.45) ESR1ESR2KDM1AHDAC1SMN1; SMN2
SCHEMBL6437026 0.94 HDAC1 (0.45) ESR1ESR2KDM1AHDAC1SMN1; SMN2
SCHEMBL6438538 0.88 HDAC1 (0.47) ESR1ESR2KDM1AHDAC1KMT2A
SCHEMBL6438541 0.88 HDAC1 (0.47) ESR1ESR2KDM1AHDAC1KMT2A
SCHEMBL6437655 0.82 ESR1 (0.43) ESR1ESR2HDAC1PTGS2SMN1; SMN2
SCHEMBL6441021 0.82 HDAC1 (0.45) ESR1ESR2KDM1AHDAC1SMN1; SMN2
SCHEMBL6437657 0.82 ESR1 (0.43) ESR1ESR2HDAC1PTGS2SMN1; SMN2
SCHEMBL5114409 0.82 HDAC1 (0.45) ESR1ESR2KDM1AHDAC1SMN1; SMN2
SCHEMBL14289701 0.82 ESR1 (0.39) ESR1ESR2KDM1AHDAC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6927224-B2 Selective estrogen receptor modulators BRISTOL MYERS SQUIBB COMPANY (US) 2005-08-09 — — US claimed
EP-1417169-A2 SELECTIVE ESTROGEN RECEPTOR MODULATORS Bristol-Myers Squibb Pharma Company (US) 2004-05-12 — — EP claimed
US-20030105148-A1 Selective estrogen receptor modulators BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-06-05 — — US claimed
WO-2003016270-A2 SELECTIVE ESTROGEN RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2003-02-27 — — WO claimed
US-6927224-B2 Selective estrogen receptor modulators BRISTOL MYERS SQUIBB COMPANY (US) 2005-08-09 — — US disclosed
EP-1417169-A2 SELECTIVE ESTROGEN RECEPTOR MODULATORS Bristol-Myers Squibb Pharma Company (US) 2004-05-12 — — EP disclosed
US-20030105148-A1 Selective estrogen receptor modulators BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-06-05 — — US disclosed
WO-2003016270-A2 SELECTIVE ESTROGEN RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2003-02-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105148-A1 Selective estrogen receptor modulators ESR1, GPER1, PTGIR ESR1 1/4885ESR2 8/4885KDM1A 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.